Clinical Trials Logo

Coronary Disease clinical trials

View clinical trials related to Coronary Disease.

Filter by:

NCT ID: NCT00590174 Completed - Clinical trials for Coronary Artery Disease

Clopidogrel Use and Long-term Safety After Drug-Eluting Stents Implantation

ZEST-LATE
Start date: October 2007
Phase: Phase 4
Study type: Interventional

The purpose of ZEST-LATE (Evaluation of the Long-term Safety After Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or PacliTaxel-Eluting Stent Implantation for Coronary Lesions - Late Coronary Arterial Thrombotic Events) trial is to assess the relationship between long-term clopidogrel use beyond 1 year and long-term rates of death or MI after DES implantation and to estimate the duration of dual antiplatelet therapy for preventing the late thrombotic events.

NCT ID: NCT00589927 Completed - Clinical trials for Coronary Artery Disease

Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent

DECLARELONG
Start date: December 2007
Phase: Phase 4
Study type: Interventional

To evaluate whether the cilostazol reduce neointimal hyperplasia after ZES (Zotarolimus-eluting stents) implantation, the investigators performed double-blind,randomized, multicenter, prospective study compared triple antiplatelet therapy (aspirin plus clopidogrel plus cilostazol) and dual antiplatelet therapy (aspirin plus clopidogrel) for 8 months in patients with long coronary lesion treated with ZES.

NCT ID: NCT00589732 Completed - Clinical trials for Coronary Artery Disease

Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent

VAL-SUPPRES
Start date: September 2006
Phase: Phase 4
Study type: Interventional

To evaluate that angiotensin-converting enzyme (ACE) inhibitors and angiotensin-converting enzyme receptor blockers (ARBs) reduce the risk of restenosis after DES implantation.

NCT ID: NCT00586950 Completed - Coronary Disease Clinical Trials

123I-BMIPP SPECT Analysis for Decreasing Cardiac Events in Hemodialysis Patients

B-SAFE
Start date: June 2006
Phase: N/A
Study type: Observational

The aim of this multi-center study is to determine the applicability of BMIPP to diagnosing cardiac disease and to predicting the outcome of patients on hemodialysis.

NCT ID: NCT00585663 Completed - Clinical trials for Coronary Artery Disease

Accuracy of Radiolabeled Fatty Acid Analog, BMIPP, in the Late Detection of Decreased Blood Flow to the Heart

ZEUSS-ACS
Start date: August 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to: - evaluate the performance characteristics (sensitivity & specificity) of iodofiltic acid I-123 imaging for detection of myocardial ischemia in patients that present in the Emergency Department with suspected Acute Coronary Syndrome (ACS). - evaluate the safety of a single injection of iodofiltic acid I-123 in patients suspected of myocardial ischemia related to ACS.

NCT ID: NCT00584818 Completed - Healthy Clinical Trials

Dose Finding Study of PB127 Ultrasound Contrast Agent in Healthy Volunteers and Patients With Coronary Artery Disease

Start date: November 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the dose of PB127 for detection and/or exclusion of coronary artery disease when used with cardiac ultrasound. This study also evaluates the safety of PB127.

NCT ID: NCT00581399 Completed - Clinical trials for Coronary Artery Disease

A Randomized Multicenter Clinical Study On the High Vacuum Body Cavity Drainage System Following Open Heart Surgery

NO-NUMO
Start date: September 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare a new high vacuum pressure chest drainage system (NO-NUMO™) with the standard low vacuum pressure drainage system already in use in cardiac surgeries. The new system uses smaller diameter drainage tubing to remove blood from the chest after open heart surgery. This is less painful to the patient and should help the patient to breathe better after operation. Preliminary data suggests that the high vacuum suction is effective and practical, and could actually reduce the amount of chest tube bleeding after surgery without compromising heart function. This new high vacuum drainage system was approved by the FDA in 2002. Subsequent testing at University of California, Irvine indicated that this unique system may allow the surgeon to predict excessive postoperative bleeding before the patient is transferred out of the operating room, thus adding safety, convenience, and cost effectiveness to their use.

NCT ID: NCT00580008 Completed - Clinical trials for Coronary Artery Disease

Evaluation Using Computed Tomography Angiography (CTA) to Investigate and Detect Atherosclerotic Graft Disease (ELUCIDATE)

ELUCIDATE)
Start date: December 2007
Phase: N/A
Study type: Observational

The purpose of clinical research is to look at the nature of disease and try to develop improved methods to diagnose and treat disease.The goal of this study is to evaluate the use of computed tomography (CT) scan of the heart in the diagnosis of disease in vein grafts after bypass surgery.

NCT ID: NCT00574782 Completed - Diabetes Clinical Trials

Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE)

CHALLENGE
Start date: September 2003
Phase: N/A
Study type: Observational

In an observational multi-centre study (CHALLENGE), the effects were assessed of starting treatment with low doses of rosuvastatin in statin naive patients with a history of coronary heart disease (CHD), peripheral vascular disease (PVD), cerebrovascular accident (CVA), transient ischemic attack (TIA) or diabetes (DM), on low-density lipoprotein cholesterol (LDL-C) goal achievement. Also proportional changes in LDL-C, high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), triglycerides (TG) and the ratio TC/HDL-C were studied.

NCT ID: NCT00570089 Completed - Myocardial Ischemia Clinical Trials

Microvascular Coronary Disease In Women: Impact Of Ranolazine

Start date: April 2007
Phase: Phase 2
Study type: Interventional

1. To evaluate the impact of ranolazine extended-release tablets in women with subendocardial ischemia due to microvascular endothelial dysfunction on myocardial ischemia (Cardiac Magnetic Resonance (CMR) extent, severity. 2. To evaluate the impact of ranolazine extended-release tablets in women with subendocardial ischemia due to microvascular endothelial dysfunction on the outcomes of angina (Seattle Angina Questionnaire (SAQ), WISE angina frequency, Duke Activity Status Inventory(DASI) and SF-36).